pharmaphorum

JANUARY 5, 2022

The FDA thinks an antibody-drug conjugate (ADC) developed by AbbVie could set new standards in treatment for certain patients with lung cancer, awarding the drug breakthrough status. overall response rate (ORR) in patients with high levels of c-Met expression, and 25% in those with intermediate levels, showing proof of concept for the ADC.

Antibody 110

Antibody Drugs Protein Gene 110

pharmaphorum

DECEMBER 23, 2021

Daiichi Sankyo has been granted breakthrough status by the FDA for patritumab deruxtecan, a HER3-targeted antibody-drug conjugate (ADC) in clinical trials for lung cancer. Daiichi Sankyo and AZ are close collaborators in the ADC arena. The post FDA gives Daiichi Sankyo’s HER3 drug a breakthrough tag appeared first on.

Drugs 71

Drugs Antibody Clinical Trials Clinical Trials 71

pharmaphorum

APRIL 27, 2022

The coveted status has been awarded to the HER2-targeting antibody-drug conjugate (ADC) on the back of the DESTINY-Breast04 trial results, unveiled in February, which involved patients with HER2-low, unresectable and/or metastatic breast cancer previously treated with one to two prior lines of chemotherapy. .”

Sales 58

Sales Drugs Antibody Licensing 58

pharmaphorum

OCTOBER 29, 2021

Gilead is sponsoring the new study to see if adding Trodelvy can be an alternative chemo when added to Keytruda in the first-line treatment of advanced TNBC, in the hope of moving the ADC up the treatment pathway. The post Gilead tags Merck for first-line triple negative breast cancer trial appeared first on.

Trials 52

Trials Sales FDA Approval Production 52

pharmaphorum

JULY 25, 2022

” GSK’s antibody-drug conjugate (ADC) Blenrep (belantamab mafodotin) was the first BCMA-targeting drug to reach the market in 2020, and has since been joined by Carvykti as well as Bristol-Myers Squibb and bluebird bio rival CAR-T therapy Abecma (idecabtagene vicleucel). .”

Antibody 52

Antibody Medicine Drugs Trials 52

Drug Discovery World

JUNE 14, 2023

We have now our lead product in a Phase I/II study, which is a HER-2 directed tag T cell product for patients with HER-2 positive solid tumours. ADCs have made a lot of headway, a lot of successes. I’ve been with a company for more than five years now. We’ve been working on the technology for many years.

Research 52

Research Engineer In-Vivo Production 52

Drug Discovery World

NOVEMBER 13, 2023

Yunying Chen, Vice President, Biologics Innovation & Discovery (BID), WuXi Biologics, on: ‘Targeting TAAs to fight cancers: Choice between TCE and ADC’. Fabian Mohr, PhD, Vice President Research & Development, IBA Lifesciences, on: ‘Developing a robust affinity tag platform using engineered streptavidin’.

Protein 59

Protein Antibody Engineer Scientist 59